$EXPO

JPMorgan Chase & Co. Sells 157,457 Shares of Exponent, Inc. $EXPO

JPMorgan Chase & Co. reduced its stake in Exponent, Inc. (NASDAQ:EXPO) by 24.7% in the third quarter, selling over 157,000 shares, though still holding 480,624 shares valued at $33.39 million. While other institutional investors made significant purchases, company insiders, including the CEO and a VP, sold a combined 9,583 shares. Exponent, which analysts rate a "Moderate Buy" with a $92.50 average target, recently beat earnings estimates and increased its quarterly dividend.

Original reporting
MarketBeat · MarketBeat
Published Mar 23, 2026, 9:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 23, 2026, 9:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JPMorgan Chase & Co. Sells 157,457 Shares of Exponent, Inc. $EXPO — source image
Decision brief

The 30-second read

$EXPONeutralMed
01

Why it matters

While insider sales and institutional reductions can signal caution, the company's solid earnings and dividend increase suggest underlying strength.

02

Market read

The news has moderate relevance for traders focusing on the financial sector and mid-cap stocks like EXPO.

03

What to watch

Potential macroeconomic factors or upcoming earnings reports could influence stock movement beyond current news.

Timing: short-term (next 1-2 weeks)

Background

JPMorgan's sale reduced its stake by 24.7%, possibly reflecting strategic rebalancing or profit-taking.

Company-level read

Ticker impact

$EXPONeutralMedium confidence
Context

The news involves a significant institutional stake reduction and insider sales, which may signal caution or a shift in perception.

Expected impact

Potential short-term decline of 2-4%, with long-term stability if fundamentals hold.

Evidence & confidence

Insider sales and reduction in institutional holdings could indicate caution, but strong earnings and dividend growth support stability.

Market effects

The financial services sector may experience slight volatility due to institutional trading patterns.

Limited regional impact; primarily affects U.S.-based financial stocks.

Minimal global relevance; specific to U.S. markets and financial sector.

Counterpoint

Insider sales may be routine and not indicative of negative outlook; institutional holdings could be rebalancing without fundamental concerns.

Key entities

  • JPMorgan Chase & Co.

    Major institutional investor reducing stake in Exponent, Inc.

  • Exponent, Inc.

    Engineering and scientific consulting firm, with recent earnings beat and dividend hike.

Related articles

$EXPOMedAI 8/10

Exponent (EXPO) Q2 2026 Earnings Call Transcript

Exponent, Inc. (EXPO) reported Q2 2026 net revenues of $148.9 million, up 12% from $132.9 million a year earlier, and net income of $29.4 million, up 11%. Diluted EPS was $0.60. Management raised FY 2026 revenue guidance to 9% to 10% growth and EBITDA margin to 27.8% to 28.1%, and authorized an additional $50 million for share repurchases.

$EXPOMedAI 8/10

Exponent Q2 Earnings Call Highlights

Exponent (NASDAQ:EXPO) reported Q2 EBITDA up 16% to $42.7 million, with EBITDA margin at 28.7% of net revenue versus 27.8% a year earlier. Billable hours rose 8% to about 390,000 and utilization increased to 74%. The company repurchased $67.4 million of stock and paid $14.8 million in dividends. It raised 2026 outlook for net revenue growth of 9% to 10%.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

$AVAVMedAI 8/10

Bloomberg: US to purchase anti-drone lasers for $400 million

Bloomberg reports the Pentagon will buy laser-based counter-drone systems from AeroVironment Inc. in a deal valued at at least $400 million. The contract is expected to supply the Army with dozens of Locust systems, described as an AI-enabled laser system for tracking and disabling small and medium UAVs. AeroVironment shares rose 8.1% intraday, according to the report.